Guggenheim analyst Yatin Suneja downgrades Surrozen (NASDAQ:SRZN) from Buy to Neutral.
Novartis Shares Decline As Spin Off Sandoz’s Market Debut Falls Short of Expected Valuation
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines.